Q4 2025 Earnings: Precision Diagnostics and Endocrine Innovation Drive Growth

The fourth quarter of 2025 has emerged as a definitive turning point for mid-cap healthcare and biotechnology firms, as evidenced by the latest earnings calls from Crinetics, MDxHealth, and Baldwin. As the industry moves further away from the post-pandemic stabilization phase, the focus has shifted sharply toward commercial execution and the integration of precision medicine into standard clinical workflows. For companies like Crinetics and MDxHealth, the Q4 results represent more than just financial metrics; they signal a transition from research-heavy entities to commercial powerhouses capable of disrupting established therapeutic and diagnostic categories.

Crinetics (CRNX) reported a transformational quarter, largely driven by the progress of its lead candidate, paltusotine. As the company prepares for its anticipated commercial launch in acromegaly, the Q4 call focused heavily on the strength of its Phase 3 PATHFNDR data and the strategic build-out of its commercial infrastructure. Management emphasized that the endocrine market is ripe for a non-peptide, once-daily oral alternative to the current standard-of-care injections. This transition from a clinical-stage biotech to a commercial-stage biopharmaceutical company is a high-stakes evolution that investors are watching closely. The company’s ability to maintain a robust cash runway while scaling its sales force will be the primary narrative throughout 2026.

“

The fourth quarter of 2025 has emerged as a definitive turning point for mid-cap healthcare and biotechnology firms, as evidenced by the latest earnings calls from Crinetics, MDxHealth, and Baldwin.

Simultaneously, MDxHealth (MDXH) demonstrated the growing market dominance of its molecular diagnostic suite for prostate cancer. Under the leadership of CEO Michael McGarrity, the company has successfully consolidated its position by offering a comprehensive pathway from early detection to treatment monitoring. The Q4 results highlighted significant volume growth in the Select mdx and Confirm mdx tests, bolstered by expanded payer coverage and inclusion in clinical guidelines. McGarrity noted that the integration of the Genomic Prostate Score (GPS) test, acquired from Exact Sciences, has provided a significant tailwind, allowing the company to capture a larger share of the urology market. The focus for MDxHealth remains on achieving sustainable profitability through operational leverage and the continued displacement of traditional, less accurate diagnostic methods.